| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UCN |
| Uniprot No | P55089 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-124aa |
| 氨基酸序列 | MRQAGRAALLAALLLLVQLCPGSSQRSPEAAGVQDPSLRWSPGARNQGGGARALLLLLAERFPRRAGPGRLGLGTAGERPRRDNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSVGK |
| 预测分子量 | 13,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UCN(Urocortin)重组蛋白的3条参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：**"Expression and Purification of Recombinant Human Urocortin in Escherichia coli"**
**作者**：Zhang Y, et al.
**摘要**：该研究描述了在大肠杆菌中高效表达重组人UCN蛋白的方法，通过优化表达条件和纯化步骤获得高纯度蛋白，并验证其体外生物活性(如激活CRF受体信号通路的能力)。
---
2. **文献名称**：**"Cardioprotective Effects of Recombinant Urocortin in Ischemia-Reperfusion Injury Models"**
**作者**：Li X, et al.
**摘要**：探讨了重组UCN蛋白在心肌缺血再灌注损伤中的作用，通过动物实验证明其能减少细胞凋亡、抑制炎症反应，并揭示其通过AMPK信号通路发挥保护作用的机制。
---
3. **文献名称**：**"Structural Characterization and Functional Analysis of Urocortin Analogues for Therapeutic Development"**
**作者**：Wang H, et al.
**摘要**：利用NMR和分子动力学模拟解析了UCN重组蛋白及其类似物的三维结构，设计出稳定性更高的突变体，并在神经退行性疾病模型中验证其增强的神经保护功能。
---
(注：以上文献信息为示例，实际引用需以真实发表的论文为准。)
Urocortin (UCN) is a neuropeptide belonging to the corticotropin-releasing hormone (CRH) family, first identified in the early 1990s. It shares structural and functional similarities with CRH but exhibits distinct receptor-binding affinities. UCN primarily binds to CRH receptor type 2 (CRHR2), playing critical roles in stress response, energy homeostasis, and cardiovascular regulation. Its involvement in modulating anxiety, depression, and inflammatory processes has made it a focal point in neuroscience and therapeutic research.
Recombinant UCN proteins are engineered using genetic cloning techniques, often expressed in bacterial (e.g., E. coli) or mammalian cell systems. These systems enable large-scale production of purified, bioactive UCN for experimental and clinical applications. The recombinant form retains the native peptide’s ability to activate CRHR2. facilitating studies on intracellular signaling pathways, such as cAMP/PKA and MAPK cascades, linked to stress adaptation and metabolic regulation.
In biomedical research, recombinant UCN is utilized to explore its therapeutic potential in heart failure, hypertension, and metabolic syndromes due to its cardioprotective and vasodilatory effects. Preclinical studies highlight its ability to reduce infarct size, improve cardiac output, and suppress appetite. However, challenges remain in optimizing delivery methods and minimizing off-target effects, as CRH receptors are widely distributed in the brain and peripheral tissues.
Recent advances in protein engineering, including site-directed mutagenesis and fusion tags, aim to enhance UCN’s stability and tissue specificity. Ongoing clinical trials investigate its applicability in stress-related disorders and neurodegenerative diseases, underscoring its versatility as a multifunctional neuropeptide with broad translational prospects.
×
